Innovative technology engineered to enhance mitochondrial activity is instrumental in assisting individuals afflicted with androgenetic alopecia and moderate pattern hair loss. These FDA-cleared Low-Level Light Therapy caps are characterized by their soft, lightweight construction, featuring three adjustable dimming levels, two pulsating modes, and 408 diodes emitting near-infrared light at 660nm and 850nm. When combined with treatments such as PRP, Exosomes, and peptides, users may observe reductions in hair shedding, thinning, and overall hair loss.
Low-level light therapy (LLLT) for androgenetic alopecia has garnered support from multiple randomized, sham-controlled trials demonstrating substantial improvements in hair count, density, and shaft thickness compared with placebo. Additionally, it has received FDA clearance for the treatment of male and female pattern hair loss.
Meta-analyses and dermatology reviews conclude that red-light helmets and caps constitute a genuine, non-placebo intervention capable of improving early-to-moderate hair thinning. Nonetheless, the effects plateau, and ongoing maintenance is necessary, as with minoxidil or finasteride.